Observation on the Effect of Interventional Therapy Combined with Lenvatinib and Sintilimab in the Treatment of Advanced Liver Cancer

Objective: To observe the control effect of interventional therapy combined with lenvatinib and sintilimab in patients with intermediate and advanced liver cancer. Methods: 82 patients with intermediate and advanced liver cancer who visited from January 2022 to January 2025 were selected as samples and randomly divided into two groups. Group A received interventional therapy combined with lenvatinib and sintilimab, while Group B received interventional therapy combined with lenvatinib. Disease remission rate, adverse reactions, liver function indicators, and tumor marker indicators were compared between the two groups. Results: The disease control rate (DCR) in Group A was higher than that in Group B (P < 0.05). There was no difference in adverse reaction rates between Group A and Group B (P > 0.05). Total bilirubin (TBil), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) levels in Group A were lower than those in Group B (P < 0.05). Carcinoembryonic antigen (CEA), alpha-fetoprotein (AFP), and alpha-L-fucosidase (AFU) levels in Group A were also lower than those in Group B (P < 0.05). Conclusion: Intermediate and advanced liver cancer patients receiving interventional therapy combined with lenvatinib and sintilimab showed reduced tumor marker levels, lessened liver function damage, and a high disease control rate and treatment safety.